Cerivastatin

被引:38
作者
McClellan, KJ [1 ]
Wiseman, LR [1 ]
McTavish, D [1 ]
机构
[1] Adis Int Ltd, Auckland 10, New Zealand
关键词
D O I
10.2165/00003495-199855030-00009
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Cerivastatin is a synthetic HMG-CoA reductase inhibitor with high liver selectivity, which lowers plasma cholesterol levels by inhibiting endogenous cholesterol synthesis. In vitro, the affinity of cerivastatin for HMG-CoA reductase was higher than that of lovastatin, simvastatin and pravastatin. This higher enzyme affinity was reflected in vivo, with a lower ED50 (dose causing 50% inhibition) for cerivastatin in rats and beagle dogs compared with lovastatin, Cerivastatin 0.2 mg/day significantly reduced low density lipoprotein (LDL)-cholesterol, total cholesterol and triglyceride levels, and increased high density lipoprotein (HDL)-cholesterol levels, in patients with type IIa hypercholesterolaemia. Available data indicate that cerivastatin has a tolerability profile similar to that of other HMG-CoA reductase inhibitors. No drug interactions were observed when cerivastatin was coadministered with digoxin, warfarin, cimetidine or the antacid magnesium/aluminium hydroxide.
引用
收藏
页码:415 / 420
页数:6
相关论文
共 31 条
  • [1] BETTERIDGE DJ, 1997, ATHEROSCLEROSIS, P134
  • [2] BETTERIDGE DJ, 1997, CERIVASTATIN, P29
  • [3] Cerivastatin: pharmacology of a novel synthetic and highly active HMG-CoA reductase inhibitor
    Bischoff, H
    Angerbauer, R
    Bender, J
    Bischoff, E
    Faggiotto, A
    Petzinna, D
    Pfitzner, J
    Porter, MC
    Schmidt, D
    Thomas, G
    [J]. ATHEROSCLEROSIS, 1997, 135 (01) : 119 - 130
  • [4] Bischoff H, 1997, ATHEROSCLEROSIS, V130, P93
  • [5] BISCHOFF H, 1992, 11 INT S DRUGS AFF L, P69
  • [6] Boberg M, 1997, DRUG METAB DISPOS, V25, P321
  • [7] Effect of the new HMG-CoA reductase inhibitor cerivastatin (BAY W 6228) on migration, proliferation and cholesterol synthesis in arterial myocytes
    Corsini, A
    Arnaboldi, L
    Raiteri, M
    Quarato, P
    Faggiotto, A
    Paoletti, R
    Fumagalli, R
    [J]. PHARMACOLOGICAL RESEARCH, 1996, 33 (01) : 55 - 61
  • [8] Farnier M, 1997, ATHEROSCLEROSIS, V134, P123
  • [9] Cholesterol lowering with statin drugs, risk of stroke, and total mortality - An overview of randomized trials
    Hebert, PR
    Gaziano, JM
    Chan, KS
    Hennekens, CH
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1997, 278 (04): : 313 - 321
  • [10] Suppression of neointimal thickening by a newly developed HMG-CoA reductase inhibitor, BAYw6228 and its inhibitory effect on vascular smooth muscle cell growth
    Igarashi, M
    Takeda, Y
    Mori, S
    Ishibashi, N
    Komatsu, E
    Takahashi, K
    Fuse, T
    Yamamura, M
    Kubo, K
    Sugiyama, Y
    Saito, Y
    [J]. BRITISH JOURNAL OF PHARMACOLOGY, 1997, 120 (06) : 1172 - 1178